BioArctic develops a PET tracer for imaging of the brain and improved biochemical methods.
In collaboration with Uppsala University, Sweden, BioArctic is developing a new type of PET tracer for imaging of the brain in Alzheimer’s disease by using BioArctic’s antibodies. The goal is to create tools to better diagnose the disease, follow the disease progression and objectively measure the effect of drug treatment.
BioArctic develops improved biochemical methods for the identification and precise measurement of responses to treatment of Alzheimer’s disease and Parkinson’s disease, and for the measurement of disease progression in the individual patient. This is done in collaboration with the University of Gothenburg, Sweden.
Lack of biomarkers that mirror disease progression
Alzheimer’s disease is currently diagnosed by clinical investigation, in combination with tests of cognitive function, biochemical diagnostic of the cerebrospinal fluid (CSF) and brain imaging. The diagnostic procedure also includes the exclusion of other dementia diseases. There is a lack of biomarkers that can mirror disease progression.
Some biomarkers that have a direct relation to the pathogenic process have rendered a special interest for further research. Amyloid-beta42 is a secreted protein and the main constituent of the plaques in brains from patients with Alzheimer’s disease and also the component of the toxic oligomers/protofibrils.
Plaques can be visualized in the brain with PET (Positron Emission Tomography) imaging. The levels of amyloid-beta42 in CSF from patients with Alzheimer’s disease are typically lower compared to CSF obtained from healthy controls or subjects with other dementia illnesses.
Tau is a microtubule-associated protein that is highly phosphorylated in Alzheimer’s disease. Both total tau and phosphorylated tau in CSF are elevated in patients with Alzheimer’s disease. Amyloid-beta42, phosphorylated tau and total tau in CSF, are currently used as biomarkers.
Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease. Dag Sehlin. Xiaotian T. Fang, Linda Cato, Gunnar Antoni, Lars Lannfelt, Stina Syvänen, Nature Communications, Volume: 7, Article number: 10759. Published 19 Feb 2016